2026-2034年全球口服固体製剂契约製造市场规模、份额、趋势及成长分析报告

预计口服固体製剂契约製造市场将从 2025 年的 412 亿美元成长到 2034 年的 710.4 亿美元，2026 年至 2034 年的复合年增长率为 6.24%。

随着製药公司越来越多地将生产外包给专业的合约研发生产机构（CDMO），口服固体製剂（OSD）契约製造市场正经历显着成长。片剂和胶囊仍然是最常见的给药形式，推动持续的需求。外包能够优化成本、扩大生产规模并确保符合国际监管标准。

成长要素包括专利到期后学名药的生产、小分子药物研发管线的扩充以及对灵活生产能力的需求。高活性原料药（API）、连续生产和品管系统的技术进步正在提高效率。製药公司在製剂开发和商业化生产方面越来越依赖合约研发生产机构（CDMO）。

未来前景稳健，这得益于学名药和专科药市场的不断扩张。新兴经济体被列为具有成本竞争力的製造地。对自动化、数位化品管和监管合规的投资预计将加剧竞争。然而，供应链中断和严格的监管可能会对业务营运产生影响。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球口服固体製剂契约製造市场：依产品划分

• 市场分析、洞察与预测
• 药片
• 胶囊
• 粉末
• 颗粒
• 其他的

第五章：全球口服固体製剂契约製造市场：依机制划分

• 市场分析、洞察与预测
• 即时发布
• 延迟释放
• 控释

第六章：全球口服固体製剂契约製造市场：依最终用途划分

• 市场分析、洞察与预测
• 大公司
• 小型企业
• 其他的

第七章 全球口服固体製剂契约製造市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和分销通路合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Catalent Inc
  • Lonza
  • Aenova Group
  • Boehringer Ingelheim International GmbH
  • Jubilant Pharmova Limited
  • Patheon Pharma Services
  • Recipharm AB
  • Corden Pharma International
  • Siegfried Holding AG
  • Piramal Pharma Solutions
  • AbbVie Contract Manufacturing
  • Next Pharma AB

The Oral Solid Dosage Contract Manufacturing Market size is expected to reach USD 71.04 Billion in 2034 from USD 41.20 Billion (2025) growing at a CAGR of 6.24% during 2026-2034.

The oral solid dosage (OSD) contract manufacturing market has grown significantly as pharmaceutical companies outsource production to specialized contract development and manufacturing organizations (CDMOs). Tablets and capsules remain the most common drug delivery forms, driving sustained demand. Outsourcing enables cost optimization, scalability, and compliance with global regulatory standards.

Growth drivers include patent expirations leading to generic drug production, increasing small-molecule pipelines, and the need for flexible manufacturing capacity. Technological advancements in high-potency APIs, continuous manufacturing, and quality control systems enhance efficiency. Pharmaceutical firms increasingly rely on CDMOs for formulation development and commercial-scale production.

Future prospects are robust, supported by expanding generic and specialty drug markets. Emerging economies offer cost-competitive manufacturing hubs. Investment in automation, digital quality management, and regulatory compliance will strengthen competitiveness. However, supply chain disruptions and stringent regulatory scrutiny may impact operational dynamics.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Tablets
• Capsules
• Powders
• Granules
• Others

By Mechanism

• Immediate Release
• Delayed Release
• Controlled Release

By End Use

• Large Size Companies
• Medium & Small Size Companies
• Others

COMPANIES PROFILED

• Catalent Inc, Lonza, Aenova Group, Boehringer Ingelheim International GmbH, Jubilant Pharmova Limited, Patheon Pharma Services, Recipharm AB, Corden Pharma International, Siegfried Holding AG, Piramal Pharma Solutions, AbbVie Contract Manufacturing, Next Pharma AB
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Capsules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Powders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Granules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY MECHANISM 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism
• 5.2. Immediate Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Delayed Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Controlled Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Large Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Medium & Small Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Mechanism
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Mechanism
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Mechanism
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Mechanism
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Mechanism
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Catalent Inc
  • 9.2.2 Lonza
  • 9.2.3 Aenova Group
  • 9.2.4 Boehringer Ingelheim International GmbH
  • 9.2.5 Jubilant Pharmova Limited
  • 9.2.6 Patheon Pharma Services
  • 9.2.7 Recipharm AB
  • 9.2.8 Corden Pharma International
  • 9.2.9 Siegfried Holding AG
  • 9.2.10 Piramal Pharma Solutions
  • 9.2.11 AbbVie Contract Manufacturing
  • 9.2.12 Next Pharma AB